Abstract
Objective of the Paper: To demonstrate a case of successful use of tocilizumab in a child with systemic juvenile idiopathic arthritis (JIA). Key Points. A clinical variant of JIA is systemic arthritis (systemic JIA). Currently, management of systemic JIA includes tocilizumab, a recombinant humanised anti–interleukin-6 receptor monoclonal antibody. The article describes a case of successful use of tocilizumab in a child with systemic JIA after inefficient therapy with glucocorticosteroids and methotrexate. Conclusion. Systemic JIA is the severest clinical JIA variant. Tocilizumab allows achieving the quiescent disease stage where the standard therapy with glucocorticosteroids and methotrexate is ineffective. Keywords: system arthritis, juvenile idiopathic arthritis, tocilizumab, children.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
